31st Annual Scientific Meeting of
International Society of Cardiovascular Pharmacotherapy
385D
8H
6M
17S

ABOUT ISCP


The International Society of Cardiovascular Pharmacotherapy (ISCP) was created to support and promote ethical, evidence-based, cardiovascular pharmacotherapy worldwide. ISCP represents an ideal forum for open discussions on all issues related to cardiovascular pharmacotherapy and the society endeavours to foster collaboration among health professionals around the World. ISCP promotes education, research, and best clinical practice regarding the pharmacological treatment of cardiovascular conditions. ISCP ultimately aims to prevent cardiovascular disease where possible and improve patient well being through the pharmacological treatment of cardiac conditions. ISCP is a member of the World Heart Federation and currently has representatives –ISCP Governors– from over 45 countries around the World.

For more information, visit ISCP website.

ISCP EXECUTIVE COMMITTEE

  • Pablo Avanzas (Spain), President
  • Doreen Tan (Singapore), President Elect
  • Janice Wong Yii Ching (Malaysia), Secretary
  • Thomas Kahan (Sweden), Treasurer
  • Alberto Lorenzatti (Argentina), Past President 2024
  • Antoni MartĂ­nez-Rubio (Spain)
  • Felipe MartĂ­nez (Argentina)
  • Juan Carlos Kaski (UK)
  • Koji Hasegawa (Japan)
  • Gheorghe-Andrei Dan (Romania)


FULL BOARD OF DIRECTORS

  • Pablo Avanzas (Spain)
  • Celso Amodeo (Brazil)
  • Sang Hong Baek (Republic of Korea)
  • Craig Beavers (United States)
  • Gheorghe-Andrei Dan (Romania)
  • Heinz Drexel (Austria)
  • Krzysztof Filipiak, MD, PhD (Poland)
  • Alan Fong (Malaysia)
  • Koji Hasegawa (Japan)
  • Juan Carlos Kaski (UK)
  • Thomas Kahan (Sweden)
  • Alberto Lorenzatti (Argentina)
  • Felipe MartĂ­nez (Argentina)
  • Antoni MartĂ­nez-Rubio (Spain)
  • Doreen Tan (Singapore)
  • Margarita Vejar (Chile)
  • Janice Wong Yii Ching (Malaysia)
  • Georg Noll (Switzerland)


ADVISORS TO BOARD OF DIRECTORS

  • Dennis Cokkinos (Greece)
  • John McNeill (Australia)